Surrozen, Inc. · NASDAQ:SRZN
Surrozen — Investor Presentation (October 2026)
21 slides from Surrozen's investor presentation, October 2026
Slide 1: Restoring Vision Through the Science of Renewal
Restoring Vision Through the Science of Renewal © 2026 Surrozen, Inc. October 2026
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and simila
Slide 3: Designing Best-in-Disease Multi-Functional Antibodies for Retinal Vascular Disease
Designing Best-in-Disease Multi-Functional Antibodies for Retinal Vascular Disease Problem Hypothesis Assets Suboptimal treatment response and Combining vascular restoration SZN-8141 — Wnt agonism + VEGF durability with current treatments through Wnt agonism with VEGF blockade for retinal vascular d
Slide 4: Retinal Vascular Diseases (DME, wet AMD) are Large and Growing Markets with Significant Unmet Need
Retinal Vascular Diseases (DME, wet AMD) are Large and Growing Markets with Significant Unmet Need Retinal Vascular Diseases Global Anti-VEGF Agents US Prevalence1 2.7M Ophthalmic Drug Market Forecast Global >40M Prevalence2,3 $20 $18 Global Anti-VEGF ~$15B in 2025 ~$18B in 2034 $16 Market4 Annual
Slide 5: Vabysmo (VEGF + Ang2): Market Validation for VEGF Combinations
Vabysmo (VEGF + Ang2): Market Validation for VEGF Combinations Multiple targets drive additional clinical benefit Incremental drying leads to rapid adoption Vabysmo Clinical Outcomes in DME* Global Vabysmo Revenue $6.0 Vabysmo Launch $5.0 Annual Sales ($B) $4.0 $3.0 $2.0 $1.0 $0.0 © 2026 Surrozen, I
Slide 6: Wnt Signaling: A Key Regulator of Vascular Biology
Wnt Signaling A Key Regulator of Vascular Biology
Slide 7: Wnt is a Key Regulator of Retinal Vascular Function
Wnt is a Key Regulator of Retinal Vascular Function A complementary mechanism to VEGF inhibition FZD4/LRP5 Wnt Signaling Restores Blood Retina Barrier Integrity Genetic Validation FZD4 Mutations in FZD4 mediated Wnt signaling Wnt ligand (Norrin) cause Norrie disease and FEVR — both LRP5 marked by se
Slide 8: Advancing Beyond VEGF
Advancing Beyond VEGF Combining Wnt agonism with VEGF inhibition and other complementary mechanisms to drive differentiated outcomes MOA DME Study BCVA at CST at Supporting Evidence week 12 week 12 • Wnt agonism monotherapy is the Wnt agonist Restoret Ph1/2 +11.2 letters -143 um only non-VEGF monoth
Slide 9: Surrozen Advantage: Defining the Next Era of Retinal Repair
Surrozen Advantage: Defining the Next Era of Retinal Repair Pioneers in Wnt Pathway Next Generation Multifunctional Biology: Biologics: Built by the world’s leading experts who Multifunctional biologics which combine Wnt discovered the Wnt pathway, its role in tissue activation with modulation of ot
Slide 10: Our Development Pipeline
Our Development Pipeline ) Surrozen
Slide 11: Second Generation Multi-Functional Wnt Targeted Antibodies
Second Generation Multi-Functional Wnt Targeted Antibodies Complementary mechanisms enable potential best-in-disease antibodies SZN-8141 – WNT Activation + VEGF Inhibition Wnt activation via FZD4/LRP5 • Potential for best-in-class Wnt activation • Wnt activation upregulates tight junction proteins a
Slide 12: SZN-8141 Restores Retinal Vessel Architecture
SZN-8141 Restores Retinal Vessel Architecture Oxygen Induced Retinopathy Model Avascular area Retinal flat mount Control SZN-8141 10 Avascular area (% of total area) 8 80% reduction in Novel mechanism for treatment of avascular area © 2026 Surrozen, Inc. 6 retinal vascular diseases that has been obs
Slide 13: SZN-8141 VEGF Binding Domains Neutralize Pathologic VEGF-A
SZN-8141 VEGF Binding Domains Neutralize Pathologic VEGF-A In vitro assays demonstrate similar potency, affinity and binding to aflibercept KDR/NFAT-RE HEK293 Binding Affinity Cell Potency Assay to VEGF (Kd) 5000000 4000000 SZN-8141 Aflibercept <1pM <1pM 3000000 RLU 2000000 Aflibercept 1000000 SZN-8
Slide 14: SZN-8141 Synergy Observed with Wnt and VEGF Dual Mechanism
SZN-8141 Synergy Observed with Wnt and VEGF Dual Mechanism OIR Model (Delayed) Reduction of avascular area Avascular area (% of total area) 20 15 **** 10 **** 5 ****,# 0 Negative Anti-VEGF Wnt Agonist Anti-VEGF + SZN-8141 Control Wnt Agonist Reduction of neovascularization Neovascular area (% of tot
Slide 15: DUET: A Phase 1b/2a Study of SZN-8141 in Diabetic Macular Edema
DUET: A Phase 1b/2a Study of SZN-8141 in Diabetic Macular Edema First patient dosing expected 4Q 2026; initial data expected 2H 2027 Part 1: First-in-Human Part 2: Phase 2a Dose Expansion Single ascending dose Randomized, head-to-head vs. Vabysmo • Open-label single-ascending- • Randomized, double-m
Slide 16: SZN-8143: Targeting IL-6 Could Provide Additional Clinical Benefit in UME
SZN-8143: Targeting IL-6 Could Provide Additional Clinical Benefit in UME and Other Retinal Vascular Diseases SZN-8143 – WNT + VEGF + IL-6 Wnt activation via FZD4/LRP5 Fv:VHH Additional Fc IL-6 inhibition via anti-IL-6 IgG engineering to reduce liabilities • Reduces vascular permeability and VEGF pr
Slide 17: Wnt Biology Supports Multiple Therapeutics Opportunities in Ophthalmology
Wnt Biology Supports Multiple Therapeutics Opportunities in Ophthalmology Pipeline Wnt agonists show promising preclinical activity across multiple disease models Fuchs’ Endothelial Dystrophy Program • Loss of corneal endothelial cells causes corneal swelling, haziness and vision loss, accompanied b
Slide 18: Ophthalmology Franchise: Multiple Novel Candidates
Ophthalmology Franchise: Multiple Novel Candidates PROGRAM INDICATION RESEARCH PRE-CLINICAL PHASE 1 SZN-8141 wet AMD, DME FZD4, VEGF SZN-8143 wet AMD, DME, UME FZD4, VEGF, IL-6 Research Ocular disease SZN-413* Retinopathies FZD4 © 2026 Surrozen, Inc. Glossary: FZD - frizzled; VEGF - Vascular Endothe
Slide 19: Surrozen: Developing the Next Generation of Retinal Therapeutics
Surrozen: Developing the Next Generation of Retinal Therapeutics 1 2 3 Differentiated approach First-in-class biologics Best-in-disease potential Wnt biology offers a SZN-8141 is a novel biologic DUET is designed to determine differentiated therapeutic combining Wnt agonism and whether this biology
Slide 20: Thank You
Thank You www.surrozen.com © 2026 Surrozen, Inc. October 2026
Slide 21: Glossary
Glossary AMD Age-related macular degeneration IVT Intravitreal BCVA Best-corrected visual acuity Lrp Lipoprotein receptor-related protein CST Central subfield thickness PK Pharmacokinetics DME Diabetic macular edema POC Proof-of-concept ECM Extracellular matrix OIR Oxygen induced retinopathy EOS End